SG11202009793TA - Shp2 inhibitor compositions, methods for treating cancer and methods for identifying a subject with shp2 mutations - Google Patents
Shp2 inhibitor compositions, methods for treating cancer and methods for identifying a subject with shp2 mutationsInfo
- Publication number
- SG11202009793TA SG11202009793TA SG11202009793TA SG11202009793TA SG11202009793TA SG 11202009793T A SG11202009793T A SG 11202009793TA SG 11202009793T A SG11202009793T A SG 11202009793TA SG 11202009793T A SG11202009793T A SG 11202009793TA SG 11202009793T A SG11202009793T A SG 11202009793TA
- Authority
- SG
- Singapore
- Prior art keywords
- methods
- shp2
- identifying
- subject
- treating cancer
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Immunology (AREA)
- Wood Science & Technology (AREA)
- Pathology (AREA)
- Analytical Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Physics & Mathematics (AREA)
- Molecular Biology (AREA)
- Oncology (AREA)
- Hospice & Palliative Care (AREA)
- Biophysics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Enzymes And Modification Thereof (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862655648P | 2018-04-10 | 2018-04-10 | |
| PCT/US2019/026543 WO2019199792A1 (en) | 2018-04-10 | 2019-04-09 | Shp2 inhibitor compositions, methods for treating cancer and methods for identifying a subject with shp2 mutations |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11202009793TA true SG11202009793TA (en) | 2020-10-29 |
Family
ID=66248820
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11202009793TA SG11202009793TA (en) | 2018-04-10 | 2019-04-09 | Shp2 inhibitor compositions, methods for treating cancer and methods for identifying a subject with shp2 mutations |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20210154190A1 (zh) |
| EP (1) | EP3773590A1 (zh) |
| JP (1) | JP2021521155A (zh) |
| KR (1) | KR20200143417A (zh) |
| CN (1) | CN112203689A (zh) |
| AU (1) | AU2019251207A1 (zh) |
| BR (1) | BR112020020743A2 (zh) |
| CA (1) | CA3096535A1 (zh) |
| CO (1) | CO2020012588A2 (zh) |
| IL (1) | IL277783B1 (zh) |
| MX (1) | MX2020010719A (zh) |
| SG (1) | SG11202009793TA (zh) |
| TW (1) | TW201946627A (zh) |
| WO (1) | WO2019199792A1 (zh) |
Families Citing this family (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11466017B2 (en) | 2011-03-10 | 2022-10-11 | Board Of Regents, The University Of Texas System | Heterocyclic inhibitors of PTPN11 |
| JO3517B1 (ar) | 2014-01-17 | 2020-07-05 | Novartis Ag | ان-ازاسبيرو الكان حلقي كبديل مركبات اريل-ان مغايرة وتركيبات لتثبيط نشاط shp2 |
| WO2017210134A1 (en) | 2016-05-31 | 2017-12-07 | Board Of Regents, University Of Texas System | Heterocyclic inhibitors of ptpn11 |
| MX2018015625A (es) | 2016-06-14 | 2019-03-06 | Novartis Ag | Compuestos y composiciones para inhibir la actividad de shp2. |
| SG11201900157RA (en) | 2016-07-12 | 2019-02-27 | Revolution Medicines Inc | 2,5-disubstituted 3-methyl pyrazines and 2,5,6-trisubstituted 3-methyl pyrazines as allosteric shp2 inhibitors |
| EP3515916B1 (en) | 2016-09-22 | 2023-06-07 | Relay Therapeutics, Inc. | Shp2 phosphatase inhibitors and methods of use thereof |
| TW201819386A (zh) | 2016-10-24 | 2018-06-01 | 美商傳達治療有限公司 | Shp2磷酸酶抑制劑及其使用方法 |
| EP3571189B1 (en) | 2017-01-23 | 2023-03-29 | Revolution Medicines, Inc. | Pyridine compounds as allosteric shp2 inhibitors |
| JP7240319B2 (ja) | 2017-01-23 | 2023-03-15 | レヴォリューション・メディスンズ，インコーポレイテッド | アロステリックｓｈｐ２阻害剤としての二環式化合物 |
| EP3630770A1 (en) | 2017-05-26 | 2020-04-08 | Relay Therapeutics, Inc. | Pyrazolo[3,4-b]pyrazine derivatives as shp2 phosphatase inhibitors |
| WO2019051084A1 (en) | 2017-09-07 | 2019-03-14 | Revolution Medicines, Inc. | SHP2 INHIBITOR COMPOSITIONS AND METHODS OF TREATING CANCER |
| US11701354B2 (en) | 2017-09-29 | 2023-07-18 | D. E. Shaw Research, Llc | Pyrazolo[3,4-b]pyrazine derivatives as SHP2 phosphatase inhibitors |
| WO2019075265A1 (en) | 2017-10-12 | 2019-04-18 | Revolution Medicines, Inc. | PYRIDINE, PYRAZINE AND TRIAZINE COMPOUNDS AS ALLOSTERIC INHIBITORS OF SHP2 |
| MX2020006273A (es) | 2017-12-15 | 2020-09-14 | Revolution Medicines Inc | Compuestos policiclicos como inhibidores alostericos de shp2. |
| TW202003471A (zh) | 2018-03-21 | 2020-01-16 | 美商傳達治療有限公司 | Shp2磷酸酶抑制劑及其使用方法 |
| MX2020011528A (es) | 2018-05-02 | 2021-02-09 | Navire Pharma Inc | Inhibidores heterociclicos sustituidos de ptpn11. |
| EP4356973A2 (en) | 2018-08-10 | 2024-04-24 | Navire Pharma, Inc. | 6-(4-amino-3-methyl-2-oxa-8-azaspiro[4.5]decan-8-yl)-3-(2,3-dichlorophenyl)-2-methylpyrimidin-4(3h)-one derivatives and related compounds as ptpn11 (shp2) inhibitors for treating cancer |
| WO2020072656A1 (en) | 2018-10-03 | 2020-04-09 | Gilead Sciences, Inc. | Imidozopyrimidine derivatives |
| CN111138412B (zh) | 2018-11-06 | 2023-09-15 | 上海奕拓医药科技有限责任公司 | 一种螺芳环化合物及其应用 |
| CN111647000B (zh) | 2019-03-04 | 2021-10-12 | 勤浩医药（苏州）有限公司 | 吡嗪类衍生物及其在抑制shp2中的应用 |
| CN114190090A (zh) | 2019-06-07 | 2022-03-15 | 锐新医药公司 | Shp2抑制剂{6-[(2-氨基-3-氯吡啶-4-基)硫烷基]-3-[(3s,4s)-4-氨基-3-甲基-2-氧杂-8-氮杂螺[4.5]癸烷-8-基]-5-甲基吡嗪-2-基}甲醇的固体形式 |
| EP4034539A1 (en) | 2019-09-24 | 2022-08-03 | Relay Therapeutics, Inc. | Shp2 phosphatase inhibitors and methods of making and using the same |
| CN112724145A (zh) * | 2019-10-14 | 2021-04-30 | 杭州雷索药业有限公司 | 用于抑制shp2活性的吡嗪衍生物 |
| CN114901662A (zh) | 2019-11-08 | 2022-08-12 | 锐新医药公司 | 双环杂芳基化合物及其用途 |
| WO2021110796A1 (en) * | 2019-12-04 | 2021-06-10 | Bayer Aktiengesellschaft | Inhibitors of shp2 |
| CN111265529B (zh) * | 2020-02-22 | 2021-07-23 | 南京大学 | 蛋白酪氨酸磷酸酶shp2抑制剂在制备治疗银屑病药物中的应用 |
| WO2021171261A1 (en) | 2020-02-28 | 2021-09-02 | Novartis Ag | A triple pharmaceutical combination comprising dabrafenib, an erk inhibitor and a shp2 inhibitor |
| KR20240007279A (ko) * | 2021-05-13 | 2024-01-16 | 상하이 인스티튜트 오브 마테리아 메디카 차이니즈 아카데미 오브 싸이언시즈 | Shp2활성을 억제하는 헤테로고리 화합물, 이의 제조 방법 및 용도 |
| WO2022259157A1 (en) | 2021-06-09 | 2022-12-15 | Novartis Ag | A triple pharmaceutical combination comprising dabrafenib, trametinib and a shp2 inhibitor |
| TW202317100A (zh) | 2021-06-23 | 2023-05-01 | 瑞士商諾華公司 | 包含ｋｒａｓ ｇ１２ｃ抑制劑的藥物組合及其用於治療癌症之用途 |
| KR20240055778A (ko) | 2021-09-01 | 2024-04-29 | 노파르티스 아게 | Tead 억제제를 포함하는 제약 조합물 및 암의 치료를 위한 이의 용도 |
| CN116063307A (zh) * | 2021-10-29 | 2023-05-05 | 中国药科大学 | Shp2与cdk4/6双靶点抑制化合物合成及其制备方法与应用 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5262564A (en) | 1992-10-30 | 1993-11-16 | Octamer, Inc. | Sulfinic acid adducts of organo nitroso compounds useful as retroviral inactivating agents anti-retroviral agents and anti-tumor agents |
| ATE441727T1 (de) * | 2001-10-01 | 2009-09-15 | Sinai School Medicine | Noonansyndromgen |
| EP1948827B1 (en) * | 2005-10-21 | 2016-03-23 | The Regents of The University of California | C-kit oncogene mutations in melanoma |
| AU2010284255B2 (en) | 2009-08-17 | 2016-11-17 | Memorial Sloan-Kettering Cancer Center | Heat shock protein binding compounds, compositions, and methods for making and using same |
| US8673913B2 (en) * | 2009-11-13 | 2014-03-18 | Case Western Reserve University | SHP-2 phosphatase inhibitor |
| EP2826586A1 (en) | 2013-07-18 | 2015-01-21 | Siemens Aktiengesellschaft | A method and a system for machining an object |
| ES2699351T3 (es) | 2014-01-17 | 2019-02-08 | Novartis Ag | Derivados de 1-piridazin/triazin-3-il-piper(-azina)/idina/pirolidina y composiciones de las mismas para inhibir la actividad de SHP2 |
| US9815813B2 (en) | 2014-01-17 | 2017-11-14 | Novartis Ag | 1-(triazin-3-yl/pyridazin-3-yl)-piper(-azine)idine derivatives and compositions therefor for inhibiting the activity of SHP2 |
| JO3517B1 (ar) * | 2014-01-17 | 2020-07-05 | Novartis Ag | ان-ازاسبيرو الكان حلقي كبديل مركبات اريل-ان مغايرة وتركيبات لتثبيط نشاط shp2 |
| EP3310771B1 (en) | 2015-06-19 | 2020-07-22 | Novartis AG | Compounds and compositions for inhibiting the activity of shp2 |
| CN112625028A (zh) | 2015-06-19 | 2021-04-09 | 诺华股份有限公司 | 用于抑制shp2活性的化合物和组合物 |
| ES2741746T3 (es) | 2015-06-19 | 2020-02-12 | Novartis Ag | Compuestos y composiciones para inhibir la actividad de SHP2 |
| US11008372B2 (en) | 2015-11-07 | 2021-05-18 | Board Of Regents, The University Of Texas System | Targeting proteins for degradation |
| WO2017156397A1 (en) | 2016-03-11 | 2017-09-14 | Board Of Regents, The University Of Texas Sysytem | Heterocyclic inhibitors of ptpn11 |
| CA3026784A1 (en) | 2016-06-07 | 2017-12-14 | Jacobio Pharmaceuticals Co., Ltd. | Heterocyclic pyrazine derivatives useful as shp2 inhibitors |
| SG11201900157RA (en) * | 2016-07-12 | 2019-02-27 | Revolution Medicines Inc | 2,5-disubstituted 3-methyl pyrazines and 2,5,6-trisubstituted 3-methyl pyrazines as allosteric shp2 inhibitors |
-
2019
- 2019-04-09 CN CN201980037528.7A patent/CN112203689A/zh active Pending
- 2019-04-09 SG SG11202009793TA patent/SG11202009793TA/en unknown
- 2019-04-09 EP EP19719088.7A patent/EP3773590A1/en active Pending
- 2019-04-09 MX MX2020010719A patent/MX2020010719A/es unknown
- 2019-04-09 KR KR1020207032251A patent/KR20200143417A/ko active Search and Examination
- 2019-04-09 AU AU2019251207A patent/AU2019251207A1/en active Pending
- 2019-04-09 TW TW108112247A patent/TW201946627A/zh unknown
- 2019-04-09 IL IL277783A patent/IL277783B1/en unknown
- 2019-04-09 JP JP2020555352A patent/JP2021521155A/ja active Pending
- 2019-04-09 BR BR112020020743-8A patent/BR112020020743A2/pt unknown
- 2019-04-09 WO PCT/US2019/026543 patent/WO2019199792A1/en unknown
- 2019-04-09 CA CA3096535A patent/CA3096535A1/en active Pending
-
2020
- 2020-10-06 US US17/064,317 patent/US20210154190A1/en active Pending
- 2020-10-09 CO CONC2020/0012588A patent/CO2020012588A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| TW201946627A (zh) | 2019-12-16 |
| MX2020010719A (es) | 2020-11-06 |
| CO2020012588A2 (es) | 2020-10-30 |
| IL277783B1 (en) | 2024-03-01 |
| WO2019199792A1 (en) | 2019-10-17 |
| AU2019251207A1 (en) | 2020-11-19 |
| KR20200143417A (ko) | 2020-12-23 |
| BR112020020743A2 (pt) | 2021-02-02 |
| US20210154190A1 (en) | 2021-05-27 |
| CN112203689A (zh) | 2021-01-08 |
| CA3096535A1 (en) | 2019-10-17 |
| JP2021521155A (ja) | 2021-08-26 |
| EP3773590A1 (en) | 2021-02-17 |
| IL277783A (en) | 2020-11-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL277783A (en) | SHP2 inhibitory compositions, methods for treating cancer and methods for identifying a subject with SHP2 mutations | |
| IL272877A (en) | SHP2 inhibitory compositions and methods for cancer treatment | |
| ZA202006627B (en) | Methods and compositions for treating cancer | |
| IL272470A (en) | Methods and materials for the evaluation and treatment of cancer | |
| IL288914A (en) | Preparations and methods for the treatment of cancer | |
| IL284199A (en) | CSF1R inhibitors for cancer treatment | |
| IL282663A (en) | BT1718 for use in cancer treatment | |
| IL286350A (en) | Preparations and methods for the treatment of cancer | |
| IL277629A (en) | RET inhibitor for use in the treatment of cancer involving a change in RET | |
| IL288086A (en) | Methods and materials for cancer treatment | |
| IL287982A (en) | Preparations and methods for the treatment of cancer | |
| SG11202012435UA (en) | Compositions and methods for treating cancer | |
| ZA202104870B (en) | Methods and compositions for treating cancer | |
| EP4025590A4 (en) | METHODS AND COMPOSITIONS FOR TREATING CANCER | |
| IL282478A (en) | Materials and methods for cancer treatment | |
| EP3966208A4 (en) | COMPOUNDS AND METHODS FOR TREATING CANCER | |
| EP3781154A4 (en) | COMPOSITIONS AND METHODS FOR TREATING KIDNEY DAMAGE | |
| IL286153A (en) | Methods and preparations for the treatment of cancer | |
| ZA202007955B (en) | Ccr5 inhibitor for use in treating cancer | |
| SG11202010911WA (en) | Methods and compositions for treating chronic urticaria | |
| IL282948A (en) | Preparations and methods for the treatment of cancer | |
| EP4077690A4 (en) | METHODS AND COMPOSITIONS FOR TREATING CANCER | |
| SG11202109336UA (en) | Methods and compositions for treating cancer | |
| IL274714A (en) | Methods and materials for cancer assessment and treatment | |
| IL288591A (en) | Methods and uses for cancer treatment |